Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Standard Therapy in Newly Diagnosed Glioblastoma
NCT03197506Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2018
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in glioblastoma (GBM) (2 arms), sponsored by Mayo Clinic. Primary endpoints: Incidence of Dose Limiting Toxicities at 189 days and Overall Survival at 18 Months. Started Jan 2018; status: active, not recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03197506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197506.